

## **PUBLICATIONS RECHERCHE CLINIQUE 2009**

1. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X. Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. *Diseases of the colon and rectum* 2009;52:1130-1136.
2. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. *The New England journal of medicine* 2009;361:1548-1559.
3. Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Toure K, Allemon MC, Warszawski J, Rouzioux C. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). *Journal of medical virology* 2009;81:217-223.
4. Azria E, Moutafoff C, Schmitz T, Le Meaux JP, Krivine A, Pannier E, Firtion G, Compagnucci A, Finkielsztejn L, Taulera O, Tsatsaris V, Cabrol D, Launay O. Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen. *Antiviral therapy* 2009;14:423-432.
5. Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. *Fundamental & clinical pharmacology* 2009;23:423-425.
6. Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, Gerard L, Lascoux-Combe C, Molina JM, Taburet AM. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial. *Antimicrobial agents and chemotherapy*;54:937-939.
7. Barbier F, Coquet I, Legriel S, Pavie J, Darmon M, Mayaux J, Molina JM, Schlemmer B, Azoulay E. Etiologies and outcome of acute respiratory failure in HIV-infected patients. *Intensive care medicine* 2009;35:1678-1686.
8. Barrail-Tran A, Mentre F, Cosson C, Piketty C, Chazallon C, Gerard L, Girard PM, Taburet AM. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. *Antimicrobial agents and chemotherapy*;54:614-619.
9. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, Treluyer JM, Leroy V, Rouzioux C, Blanche S, Dabis F. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. *Clin Infect Dis* 2009;49:1936-1945.
10. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vezinet F, Chene G, Matheron S. Good response to

## Dernière version du 15 mars

lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. *AIDS (London, England)* 2009;23:1171-1173.

11. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C. The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection. *Journal of virology* 2009;83:4854-4860.

12. Bertrand J, Treluyer JM, Panhard X, Tran A, Auleley S, Rey E, Salmon-Ceron D, Duval X, Mentre F. Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. *European journal of clinical pharmacology* 2009;65:667-678.

13. Blom-Potar MC, Bugault F, Lambotte O, Delfraissy JF, Theze J. Soluble IL-7Ralpha (sCD127) and measurement of IL-7 in the plasma of HIV patients. *Journal of acquired immune deficiency syndromes (1999)* 2009;51:104-105.

14. Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. *AIDS (London, England)* 2009;23:2029-2037.

15. Bohlius J SK, Costagliola D, Fatkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Chene G, Lundgren J, Egger M. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. *Antiviral therapy* 2009;14:1065-1074.

16. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jouglu E, Cacoub P, Salmon D, Chene G, Morlat P. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. *Clin Infect Dis* 2009;48:633-639.

17. Borgniet O, Parvaz P, Bouix C, Chevallier P, Trepo C, Andre P, Zoulim F. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. *Journal of medical virology* 2009;81:1336-1342.

18. Bottero J, Lacombe K, Guehot J, Serfaty L, Miaillhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. *Journal of hepatology* 2009;50:1074-1083.

19. Bouillon-Pichault M, Jullien V, Azria E, Pannier E, Firtion G, Krivine A, Compagnucci A, Taulera O, Finkielstejn L, Chhun S, Pons G, Launay O, Treluyer JM. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. *The Journal of antimicrobial chemotherapy* 2009;63:1223-1232.

## Dernière version du 15 mars

20. Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naïve and -experienced patients. *Antiviral therapy* 2009;14:923-929.
21. Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. *Journal of acquired immune deficiency syndromes (1999)* 2009;52:531-537.
22. Bourgarit A, Carcelain G, Samri A, Parizot C, Lafaurie M, Abgrall S, Delcey V, Vicaut E, Sereni D, Autran B. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. *J Immunol* 2009;183:3915-3923.
23. Boyd A, Lacombe K, Mialhes P, Gozlan J, Bonnard P, Molina JM, Lascoux-Combe C, Serfaty L, Gault E, Desvarieux M, Girard PM. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. *Journal of viral hepatitis*;17:65-76.
24. Breilh D, Djabarouti S, Trimoulet P, Le Bail B, Dupon M, Ragnaud JM, Fleury H, Saux MC, Thiebaut R, Chene G, Neau D. Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. *Journal of acquired immune deficiency syndromes (1999)* 2009;52:428-430.
25. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J. No relation between in-utero exposure to HAART and intrauterine growth retardation. *AIDS (London, England)* 2009;23:1235-1243.
26. Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NK, Jorgensen LB, de Mendoza C, Bhaskaran K, Gill ON, Johnson AM, Pillay D. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. *The Journal of infectious diseases* 2009;199:427-431.
27. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercie P, Pellegrin JL, Neau D, Dabis F, Morlat P, Chene G, Bonnet F. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. *Clin Infect Dis* 2009;49:1109-1116.
28. Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. *AIDS (London, England)* 2009;23:2165-2171.

29. Caron M, Vigouroux C, Bastard JP, Capeau J. Antiretroviral-Related Adipocyte Dysfunction and Lipodystrophy in HIV-Infected Patients: Alteration of the PPARgamma-Dependent Pathways. *PPAR research* 2009;2009:507141.
30. Chable-Bessia C, Meziane O, Latreille D, Triboulet R, Zamborlini A, Wagschal A, Jacquet JM, Reynes J, Levy Y, Saib A, Bennasser Y, Benkirane M. Suppression of HIV-1 replication by microRNA effectors. *Retrovirology* 2009;6:26.
31. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. *AIDS (London, England)* 2009;23:717-724.
32. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chene G, Raffi F. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. *AIDS (London, England)* 2009;23:1021-1024.
33. Cotte L, Chevallier Queyron P, Schlienger I, Trabaud MA, Brochier C, Andre P, Zoulim F. Sexually transmitted HCV infection and reinfection in HIV-infected homosexual men. *Gastroenterologie clinique et biologique* 2009;33:977-980.
34. Cotte L, Trabaud MA, Tardy JC, Brochier C, Gillibert RP, Miallhes P, Trepo C, Andre P. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. *Journal of medical virology* 2009;81:672-677.
35. Dailly E, Raffi F, Perre P, Martin J, Deslandes G, Jolliet P. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. *HIV medicine* 2009;10:586-589.
36. Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X, Krausslich HG, Hance AJ, Clavel F. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. *PLoS pathogens* 2009;5:e1000345.
37. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. *Clin Infect Dis* 2009;49:1259-1267.
38. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, Schneider V, Burgard M, Faye A, Mandelbrot L, Tubiana R, Rouzioux C. Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. *Retrovirology* 2009;6:85.
39. Delaugerre C, Denis B, Peytavin G, Palmer P, Mourez T, Le Goff J, Molina JM, Simon F. Clinical and resistance consequences of misquantification of plasma and cerebrospinal

## Dernière version du 15 mars

fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient. *Journal of clinical microbiology* 2009;47:3763-3764.

40. Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shurmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. *Antimicrobial agents and chemotherapy* 2009;53:2934-2939.

41. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. *Nucleic acids research* 2009;37:1193-1201.

42. Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. *Antimicrobial agents and chemotherapy*;54:491-501.

43. Descamps D, Lambert-Niclot S, Marcelin AG, Peytavin G, Roquebert B, Katlama C, Yeni P, Felices M, Calvez V, Brun-Vezinet F. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. *The Journal of antimicrobial chemotherapy* 2009;63:585-592.

44. Deti E, Thiebaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, Pellegrin J, Malvy D, Tchamgoue S, Dabis F, Morlat P. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. *HIV medicine* 2009.

45. Drylewicz J, Commenges D, Thiebaut R. Score Tests for Exploring Complex Models: Application to HIV Dynamics Models. *Biometrical journal* 2009.

46. Duval X, Mentre F, Rey E, Auleley S, Peytavin G, Biour M, Metro A, Goujard C, Taburet AM, Lascoux C, Panhard X, Treluyer JM, Salmon-Ceron D. Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial. *Fundamental & clinical pharmacology* 2009;23:491-500.

47. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. *AIDS (London, England)* 2009;23:817-824.

48. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chene G, Leport C, Moing VL. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS C08) cohort study. *Journal of acquired immune deficiency syndromes (1999)* 2009;51:407-415.

## Dernière version du 15 mars

49. Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, Gladysz A, Cohen-Codar I, Van PN, Taburet AM, Rouzioux C, Delfraissy JF. Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone. *Antiviral therapy* 2009;14:93-97.
50. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D. Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. *Journal of acquired immune deficiency syndromes (1999)* 2009;50:206-214.
51. Frange P, Galimand J, Goujard C, Deveau C, Ghosn J, Rouzioux C, Meyer L, Chaix ML. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. *The Journal of antimicrobial chemotherapy* 2009;64:135-141.
52. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF. Long-term (96-week) follow-up of antiretroviral-naive HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. *HIV medicine*;11:137-142.
53. Ghosn J, Mazet AA, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy JF, Chaix ML. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. *The Journal of antimicrobial chemotherapy* 2009;64:433-434.
54. Giraud C, Manceau S, Decleves X, Goffinet F, Morini JP, Chappuy H, Batteux F, Chouzenoux S, Yousif S, Scherrmann JM, Blanche S, Treluyer JM. Influence of Development, HIV Infection, and Antiretroviral Therapies on the Gene Expression Profiles of ABC Transporters in Human Lymphocytes. *Journal of clinical pharmacology*;50:226-230.
55. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, Green H, Galli L, Ramos JT, Giaquinto C, Warszawski J, Levy J. Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. *AIDS (London, England)* 2009;23:597-604.
56. Goldwirt L, Barrail-Tran A, Da Cruz M, Taburet AM, Furlan V. Quantification of raltegravir (MK0518) in human plasma by high-performance liquid chromatography with photodiode array detection. *Journal of chromatography* 2009.
57. Goujard C, Chaix ML, Lambotte O, Deveau C, Sinet M, Guergnon J, Courgnaud V, Rouzioux C, Delfraissy JF, Venet A, Meyer L. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? *Clin Infect Dis* 2009;49:982-986.
58. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D. Prevalence and comparative characteristics of long-term nonprogressors and HIV

## Dernière version du 15 mars

controller patients in the French Hospital Database on HIV. *AIDS (London, England)* 2009;23:1163-1169.

59. Guibert G, Warszawski J, Le Chenadec J, Blanche S, Benmebarek Y, Mandelbrot L, Tubiana R, Rouzioux C, Leruez-Ville M. Decreased risk of congenital cytomegalovirus infection in children born to HIV-1-infected mothers in the era of highly active antiretroviral therapy. *Clin Infect Dis* 2009;48:1516-1525.

60. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *The lancet oncology* 2009;10:1152-1159.

61. Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X. CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm<sup>3</sup>. *Antiviral therapy* 2009;14:451-457.

62. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. *AIDS (London, England)* 2009.

63. Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D. Observation plans in longitudinal studies with time-varying treatments. *Statistical methods in medical research* 2009;18:27-52.

64. Hessamfar-Bonarek M, Morlat P, Salmon D, Cacoub P, May T, Bonnet F, Rosenthal E, Costagliola D, Lewden C, Chene G. Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalite 2000 & 2005' Surveys (ANRS EN19). *International journal of epidemiology* 2009.

65. Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramiere C, Bartenschlager R, Penin F, Lotteau V, Andre P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. *PloS one* 2009;4:e4233.

66. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, Tubiana R, Poynard T, Katlama C, Lombes A, Benhamou Y. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. *Hepatology (Baltimore, Md)* 2009;49:436-442.

67. Jacquot G, Le Rouzic E, Maidou-Peindara P, Maizy M, Lefrere JJ, Daneluzzi V, Monteiro-Filho CM, Hong D, Planelles V, Morand-Joubert L, Benichou S. Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions. *PloS one* 2009;4:e7514.

## Dernière version du 15 mars

68. Laforgerie E, Boucher B, Ly TD, Maisoneuve L, Izopet J, Delaugerre C, Simon F. Sensitivity of 8 CE (European Community)-approved rapid disposable tests for anti-HIV antibody detection during and after seroconversion. *Journal of virological methods* 2009.
69. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. *AIDS (London, England)* 2009;23:897-906.
70. Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vezinet F, Aboulker JP, Yeni P. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. *The Journal of antimicrobial chemotherapy* 2009;64:118-125.
71. Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. *AIDS (London, England)* 2009;23:426-428.
72. Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. *International journal of cancer* 2009;126:1724-1731.
73. Lanoy E, Lewden C, Lievre L, Tattevin P, Boileau J, Aouba A, Chene G, Costagliola D. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates. *HIV medicine* 2009;10:236-245.
74. Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chene G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. *AIDS (London, England)* 2009;23:2199-2208.
75. Laurichesse JJ, Taieb A, Capoulade-Metay C, Katlama C, Villes V, Drobacheff-Thiebaud MC, Raffi F, Chene G, Theodorou I, Leport C. Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy? *HIV medicine* 2009.
76. Lavole A, Chouaid C, Baudrin L, Wislez M, Raguin G, Pialoux G, Girard PM, Milleron B, Cadranet J. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2009;65:345-350.
77. Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, Delaneau O, Labib T, Sladek R, Deveau C, Guillemain H, Ratsimandresy R, Montes M, Spadoni JL, Therwath A, Schachter F, Matsuda F, Gut I, Lelievre JD, Levy Y, Froguel P, Delfraissy JF, Hercberg S, Zagury JF. Genomewide association study of a rapid progression cohort identifies new

## Dernière version du 15 mars

susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). *The Journal of infectious diseases* 2009;200:1194-1201.

78. Le Vu S, Meyer L, Cazein F, Pillonel J, Semaille C, Barin F, Desenclos JC. Performance of an immunoassay at detecting recent infection among reported HIV diagnoses. *AIDS (London, England)* 2009;23:1773-1779.

79. Lecuroux C, Girault I, Boutboul F, Urrutia A, Goujard C, Meyer L, Lambotte O, Chaix ML, Martinez V, Autran B, Sinet M, Venet A. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells. *AIDS (London, England)* 2009;23:1649-1658.

80. Lecuroux C, Girault I, Urrutia A, Doisne JM, Deveau C, Goujard C, Meyer L, Sinet M, Venet A. Identification of a particular HIV-specific CD8+ T-cell subset with a CD27+ CD45RO-/RA+ phenotype and memory characteristics after initiation of HAART during acute primary HIV infection. *Blood* 2009;113:3209-3217.

81. Legrand-Abravanel F, Henquell C, Le Guillou-Guillemette H, Balan V, Mirand A, Dubois M, Lunel-Fabiani F, Payan C, Izopet J. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naïve patients infected with genotypes 1-5. *Antiviral therapy* 2009;14:723-730.

82. Lemoine M, Capeau J, Serfaty L. PPAR and Liver Injury in HIV-Infected Patients. *PPAR research* 2009;2009:906167.

83. Leport C, Bouteloup V, Rossert J, Garre M, Iordache L, Dellamonica P, Herson S, Raffi F, Chene G. Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. *Clin Infect Dis* 2009;49:1950-1954.

84. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, Boue F, Molina JM, Rouzioux C, Avettand-Fenoel V, Croughs T, Beq S, Thiebaut R, Chene G, Morre M, Delfraissy JF. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. *The Journal of clinical investigation* 2009;119:997-1007.

85. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, Taing L, Sladek R, Deveau C, Ratsimandresy R, Montes M, Spadoni JL, Lelievre JD, Levy Y, Therwath A, Schachter F, Matsuda F, Gut I, Froguel P, Delfraissy JF, Hercberg S, Zagury JF. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). *The Journal of infectious diseases* 2009;199:419-426.

86. Loulergue P, Pol S, Mallet V, Sogni P, Launay O. Why actively promote vaccination in patients with cirrhosis? *J Clin Virol* 2009;46:206-209.

87. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A, Boucherit S, Surzyn J, Meyer L, Rouzioux C. Early control of HIV-1 infection in long-term nonprogressors

## Dernière version du 15 mars

followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. *Journal of acquired immune deficiency syndromes (1999)* 2009;50:19-26.

88. Maiga AI, Descamps D, Morand-Joubert L, Malet I, Derache A, Cisse M, Koita V, Akonde A, Diarra B, Wirden M, Tounkara A, Verlinden Y, Katlama C, Costagliola D, Masquelier B, Calvez V, Marcelin AG. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. *Antimicrobial agents and chemotherapy*;54:728-733.

89. Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cisse M, Katlama C, Calvez V, Marcelin AG. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02\_AG subtypes. *Antiviral therapy* 2009;14:123-129.

90. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. *The Journal of antimicrobial chemotherapy* 2009;63:795-804.

91. Mallet VO, Vallet-Pichard A, Pol S. Human immunodeficiency virus-associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretrovirals. *Hepatology (Baltimore, Md)* 2009;50:660.

92. Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R, Rouzioux C, Warszawski J. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. *American journal of obstetrics and gynecology* 2009;200:160 e161-169.

93. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. *Antimicrobial agents and chemotherapy*;54:72-77.

94. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucchi M, Hamouda O, Prins M, Walker S, Porter K, Sabin C, Chene G. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. *AIDS (London, England)* 2009;23:1743-1753.

95. Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, Musset L. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. *Clin Infect Dis* 2009;48:123-132.

## Dernière version du 15 mars

96. Mavigner M, Delobel P, Cazabat M, Dubois M, L'Faqihi-Olive FE, Raymond S, Pasquier C, Marchou B, Massip P, Izopet J. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. *PLoS one* 2009;4:e7658.
97. Meynard JL, Lacombe K, Poirier JM, Legrand J, Morand-Joubert L, Girard PM. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. *The Journal of antimicrobial chemotherapy* 2009;63:579-584.
98. Mialhes P, Pradat P, Trepo C. Influence of aminotransferase values on liver stiffness measurement: the case of HIV-infected patients with acute viral hepatitis B or C. *HIV medicine* 2009;10:62-63.
99. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, Poizot-Martin I, Valantin MA, Bonnard P, Salmon-Ceron D, Carrieri MP. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepaviv, France, 2006-2008. *Journal of viral hepatitis* 2009.
100. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. *Clin Infect Dis* 2009;48:1138-1151.
101. Molina JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML, Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F, Aboulker JP. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). *The Journal of infectious diseases* 2009;200:206-215.
102. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chene G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczar D, Fatkenheuer G, Staszewski S, Gill J, Sterne JA. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. *Journal of acquired immune deficiency syndromes (1999)* 2009;52:357-363.
103. Mouala C, Guiguet M, Houze S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. *AIDS (London, England)* 2009;23:1997-2004.
104. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. *Critical reviews in oncology/hematology* 2009;72:10-20.
105. Mouscadet JF, Arora R, Andre J, Lambry JC, Delelis O, Malet I, Marcelin AG, Calvez V, Tchertanov L. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. *J Mol Recognit* 2009;22:480-494.

106. Nascimbeni M, Perie L, Chorro L, Diocou S, Kreitmann L, Louis S, Garderet L, Fabiani B, Berger A, Schmitz J, Marie JP, Molina TJ, Pacanowski J, Viard JP, Oksenhendler E, Beq S, Abehsira-Amar O, Cheynier R, Hosmalin A. Plasmacytoid dendritic cells accumulate in spleens from chronically HIV-infected patients but barely participate in interferon-alpha expression. *Blood* 2009;113:6112-6119.
107. Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, Cochonat K, Fontier C, Guerroumi H, Yazdanpanah Y. Characteristics of and outcomes in HIV-infected patients who return to care after loss to follow-up. *AIDS (London, England)* 2009;23:1786-1789.
108. Nicot F, Kamar N, Mariame B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. *Transpl Int* 2009.
109. Paccou J, Viget N, Legroux-Gerot I, Yazdanpanah Y, Cortet B. Bone loss in patients with HIV infection. *Joint Bone Spine* 2009;76:637-641.
110. Pasquier C, Saune K, Raymond S, Moinard N, Daudin M, Bujan L, Izopet J. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. *Journal of clinical microbiology* 2009;47:2883-2887.
111. Peretti-Watel P, Villes V, Duval X, Collin F, Reynes J, Sobel A, Protopopescu C, Chene G, Spire B, Raffi F. How do HIV-infected smokers react to cigarette price increases? Evidence from the APROCO-COPILOTE-ANRS CO8 Cohort. *Current HIV research* 2009;7:462-467.
112. Plantier JC, Djemai M, Lemee V, Reggiani A, Leoz M, Burc L, Vessiere A, Rousset D, Poveda JD, Henquell C, Gautheret-Dejean A, Barin F. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. *Journal of clinical microbiology* 2009;47:2906-2911.
113. Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Souala MF, Costagliola D. Trends in post-infection CD4 cell counts and plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005. *Journal of acquired immune deficiency syndromes (1999)* 2009;52:422-426.
114. Prisant N, Tubiana R, Lefebvre G, Lebray P, Marcelin AG, Thibault V, Rosenblum O, Bonmarchand M, Vauthier-Brouzes D, Golmard JL, Katlama C, Poirot C. HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. *Fertility and sterility* 2009.
115. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. *The Journal of antimicrobial chemotherapy* 2009;64:599-606.

116. Puissant-Lubrano B, Combadiere B, Duffy D, Wincker N, Frachette MJ, Ait-Mohand H, Verrier B, Katlama C, Autran B. Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. *Vaccine* 2009;27:3576-3583.

117. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Bruel P, Sandres-Saune K, Marchou B, Massip P, Izopet J. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. *J Clin Virol* 2009.

118. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Encinas S, Sandres-Saune K, Pasquier C, Marchou B, Massip P, Izopet J. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. *Journal of clinical microbiology* 2009;47:2292-2294.

119. Recordon-Pinson P, Anies G, Bruyand M, Neau D, Morlat P, Pellegrin JL, Groppi A, Thiebaut R, Dabis F, Fleury H, Masquelier B. HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity. *Antiviral therapy* 2009;14:551-556.

120. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, Quivy V, Vanhulle C, Lamine A, Vaira D, Demonte D, Martinelli V, Veithen E, Cherrier T, Avettand V, Poutrel S, Piette J, de Launoit Y, Moutschen M, Burny A, Rouzioux C, De Wit S, Herbein G, Rohr O, Collette Y, Lambotte O, Clumeck N, Van Lint C. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. *PLoS one* 2009;4:e6093.

121. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, Horberg M, Shafer RW. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. *The Journal of infectious diseases* 2009;200:453-463.

122. Rose T, Lambotte O, Pallier C, Delfraissy JF, Colle JH. Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. *J Immunol* 2009;182:7389-7397.

123. Rosenthal E, Salmon-Ceron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, Francois M, Burty C, Jouglu E, Costagliola D, Morlat P, Chene G, Cacoub P. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). *HIV medicine* 2009;10:282-289.

124. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, Venet A, Pancino G. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. *J Immunol* 2009;182:7828-7837.

## Dernière version du 15 mars

125. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, Bonnet F, Costagliola D, Jouglu E, Semaille C, Morlat P, Cacoub P, Chene G. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. *Journal of hepatology* 2009;50:736-745.
126. Samri A, Roque-Afonso AM, Beran O, Tateo M, Teicher E, Feray C, Sebah M, Guettier C, Dussaix E, Vittecoq D, Samuel D, Autran B, Duclos-Vallee JC. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfecting patients (ANRS-HC08 "THEVIC" trial). *Journal of hepatology* 2009;51:1000-1009.
127. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, Slama L, Simon A, Valantin MA, Thibault V, Autran B. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. *AIDS (London, England)* 2009;23:2079-2089.
128. Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. *Liver Int* 2009;29 Suppl 2:13-25.
129. Slama L, Le Camus C, Serfaty L, Pialoux G, Capeau J, Gharakhanian S. Metabolic disorders and chronic viral disease: the case of HIV and HCV. *Diabetes & metabolism* 2009;35:1-11.
130. Soulie C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. *AIDS (London, England)* 2009;23:1605-1608.
131. Stegmann S, Manea ME, Charpentier C, Damond F, Karmochkine M, Laureillard D, Si-Mohamed A, Weiss L, Piketty C. Fosarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. *J Clin Virol* 2009.
132. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009;373:1352-1363.
133. Thuret I, Chaix ML, Tamalet C, Reliquet V, Firtion G, Tricoire J, Rabaud C, Frange P, Aumaitre H, Blanche S. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. *AIDS (London, England)* 2009;23:2364-2366.
134. Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, Barrou B, Duvivier C, Fontaine C, Welker Y, Billy C, de Truchis P, Delahousse M, Vittecoq D, Salmon-Ceron D. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. *Am J Transplant* 2009;9:1946-1952.

135. Troude P, Chaix ML, Tran L, Deveau C, Seng R, Delfraissy JF, Rouzioux C, Goujard C, Meyer L. No evidence of a change in HIV-1 virulence since 1996 in France. *AIDS (London, England)* 2009;23:1261-1267.

136. Viard JP, Fagard C, Chaix ML, Rouzioux C, Bouteloup V, Bentata M, de Verdiere NC, Pahlavan G, Weiss L, Levy Y, Chene G. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients. *AIDS (London, England)* 2009;23:1383-1388.

137. Wendum D, Lacombe K, Chevallier M, Callard P, Valet F, Miaillhes P, Bonnard P, Molina JM, Lascoux-Combe C, Flejou JF, Girard PM. Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides. *Journal of clinical pathology* 2009;62:361-363.

138. Wirden M, Simon A, Schneider L, Tubiana R, Malet I, Ait-Mohand H, Peytavin G, Katlama C, Calvez V, Marcelin AG. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. *The Journal of antimicrobial chemotherapy* 2009;64:1087-1090.

139. Wittkop L, Breilh D, Da Silva D, Duffau P, Mercie P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiebaut R, Masquelier B, Pellegrin I. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. *The Journal of antimicrobial chemotherapy* 2009;63:1251-1255.

140. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Moller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). *Circulation* 2009;119:805-811.

141. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte A, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Moller N. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. *Diabetes care* 2009;32:474-480.

142. Yamamoto T, Samri A, Marcelin AG, Mitsuki YY, Vincent C, Autran B, Tsunetsugu-Yokota Y. Effect of lentivirus encoding HIV-1 Nef-U3 shRNA on the function of HIV-specific memory CD4(+) T cells in patients with chronic HIV-1 infection. *AIDS (London, England)* 2009;23:2265-2275.

143. Yazdanpanah Y. Multidrug resistance: a clinical approach. *Current opinion in HIV and AIDS* 2009;4:499-506.

## Dernière version du 15 mars

144. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina JM, Chene G. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. *Clin Infect Dis* 2009;49:1441-1449.

145. Zwahlen M HR, May M, Costagliola D, Lewden C, Justice A, Von Wyl V, Egger M,. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *International journal of epidemiology* 2009;38:1624-1633.